ASX Listed AFT Pharmaceuticals Profit Jumps 24%, Revenue Climbs Above NZ$254M
Synopsis
AFT Pharmaceuticals reported strong FY26 earnings as net profit climbed 24% to NZ$14.1 million and revenue increased 22% to NZ$254.7 million. The healthcare company said strong growth across Australia and New Zealand alongside expanding international operations helped support the result. AFT also forecast higher operating profit for FY27 and said it is targeting revenue above NZ$300 million during the current financial year. Investors responded positively to the update, pushing the company’s shares higher in early trading. Management said continued investment in product launches, licensing opportunities, and overseas expansion remains central to AFT’s long-term growth strategy.
AFT Pharmaceuticals Ltd (ASX: AFT) posted a strong FY26 with 24% growth in profit to NZ$8.354 million and 22% growth in revenue to NZ$55,64 million. Earnings was led by reasonable growth in Australia, New Zealand, Europe and the UK with more expansion plans supported.
Key Highlights
- AFT Pharmaceuticals recorded 24% increase in net profit to NZ$14.1 million
NZ$254.7 million FY21 (up 22% year-on-year) revenue - In FY27, Company expects revenue to exceed NZ$300 million
- Australian business largest earnings contributor
- Following the earnings announcement, shares rose
AFT Pharmaceuticals delivered solid FY26 earnings growth
In FY26, AFT Pharmaceuticals Ltd (NZSE: AFT) announced that net profit increased 24% to NZ$14.1 million after revenue of $254.7 million (+22% YOY). The healthcare company also announced a dividend of 5 cents per share and guidance for FY27 operating profit of NZ$28m–NZ$32m (vs NZ$24.4m in FY26). Shares in the company rose around 2.4% early-in-the-day as investors reacted positively to the solid print and additional guidance after the announcement.
Australian and International Expansion Fuel Revenues
The re-seller added that it had delivered revenue growth during FY26 despite international operations contributing 13.5% of revenues compared to 7.82% in the previous year which was complemented by robust sales across Australia and New Zealand. Revenue from its core Australasia remained the biggest earnings growth driver for the company, with regional revenue up 16% to NZ$210.5 million. Australian growth was driven by solid sales across the over-the-counter medicines and prescription product segments together with new product launches, AFT said. Additionally, as part of its long-term growth strategy, the business continued to extend internationally throughout the UK, Europe, North America and South Africa.
Management Aims Targeting NZ$300 Million Revenue
David Flack, AFT’s chair said that the company “continued to invest in long-term growth through product development, licensing opportunities and international expansion.” AFT continued the rollout of Maxigesic tablets in the UK, where it is sold as Combogesic in more pharmacies and for Combogesic IV into hospitals. The company further added that newly launched injectable products in Europe are anticipated to provide meaningful support during FY27. The company also said it is keeping the balance sheet and noted that the lower half of the year was in target range to achieve order revenue of NZ$300 million.
FAQs
- How much profit did AFT Pharmaceuticals report?
The company disclosed an FY26 net profit of NZ$14.1 million
- How much did revenue increase?
Revenue increased 22% to NZ$254.7 million.
- What is AFT planning for FY27?
The company targets revenue of above NZ$300 million.
Follow Inspirepreneur Magazine for daily global business news.
At Inspirepreneurs Magazine, covering entrepreneurship, business failures, and the human stories behind the world's most ambitious founders. She writes at the intersection of strategy and storytelling.
